Solid Tumor, Unresectable or Metastatic Melanoma
Conditions
Keywords
Combination, ipilimumab, Cancer, checkpoint inhibitor, PD-L1, CTLA-4, PROCLAIM, PROCLAIM-CX-072, Relapsed, Refractory
Brief summary
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
Interventions
DRUGCX-072
CX-072 in combination with ipilimumab
DRUGIpilimumab
CX-072 in combination with ipilimumab
Sponsors
CytomX Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. At least 18 years of age 2. Measurable disease as defined by RECIST v1.1 3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 4. Agree to provide tumor tissue and blood samples for biomarker assessment
Exclusion criteria
1. Treatment with cytotoxic chemotherapy, biologic agents, radiation, immunotherapy, or any investigational agent within 28 days prior to the first dose of study treatment. 2. Prior therapy with a chimeric antigen receptor T cell-containing regimen 3. History of active autoimmune disease(s) including but not limited to inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies, type 1 insulin-dependent diabetes mellitus 4. History of myocarditis regardless of the cause 5. History of intolerance to prior checkpoint inhibitor therapy defined as the need to discontinue treatment due to an irAE 6. History of any syndrome or medical condition that required treatment with systemic steroids (≥10 mg daily prednisone equivalents) or immunosuppressive medications. 7. History of severe allergic or anaphylactic reactions to human mAb therapy or known hypersensitivity to any Probody therapeutic
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate by RECIST v 1.1 | 1 year | ORR by RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Percentage of Patients Experiencing Treatment Related Adverse Events | 2 years | Safety and Tolerability of CX-072 in Combination Therapy |
| The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | 2 years | ORR by irRECIST |
Countries
Australia, Netherlands, South Korea, Spain, United States
Participant flow
Recruitment details
This study was composed of 2 parts (Part A and Part B) and 4 cohorts (A1, A2, A3, B1).
Pre-assignment details
Subjects who meet Inclusion / Exclusion criteria began the Screening Period within 30 days prior to the first dose of study treatment. Subjects for whom consent was provided underwent Screening Period assessments to determine eligibility for the study; assessments were to be performed within 30 days prior to the first dose of study treatment.
Participants by arm
| Arm | Count |
|---|---|
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line Histologically or cytologically confirmed solid tumor who have received no prior treatment
CX-072 in combination with ipilimumab
Part A Dosing Regimen:
* Combination treatment: 800 mg CX-072 + 3 mg/kg ipilimumab, q3w
* Monotherapy treatment: 800 mg CX-072, q2w | 0 |
| Cohort A2: CX-072 in Combination With Ipilimumab Histologically or cytologically confirmed Stage III (unresectable) or Stage IV melanoma who have experienced progressive disease or relapse following treatment with a PD-1/PD-L1 immune checkpoint inhibitor
CX-072 in combination with ipilimumab
Part A Dosing Regimen:
* Combination treatment: 800 mg CX-072 + 3 mg/kg ipilimumab, q3w
* Monotherapy treatment: 800 mg CX-072, q2w | 3 |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed Histologically or cytologically confirmed, advanced/unresectable or metastatic solid tumor that have experienced disease progression during or following treatment with platinum based therapy
CX-072 in combination with ipilimumab
Part A Dosing Regimen:
* Combination treatment: 800 mg CX-072 + 3 mg/kg ipilimumab, q3w
* Monotherapy treatment: 800 mg CX-072, q2w | 0 |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant Neo-adjuvant study in subjects with histologically confirmed solid tumor
CX-072 in combination with ipilimumab
Part B Dosing Regimen:
* Combination treatment: 800 mg CX-072 + 1 mg/kg ipilimumab, q3w
* Monotherapy treatment: 800 mg CX-072, q2w | 0 |
| Total | 3 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | The study was terminated early due to business decision. | 0 | 2 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | Cohort A2: CX-072 in Combination With Ipilimumab | Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 2 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | — | 0 Participants | — | — | 0 Participants |
| Race (NIH/OMB) Asian | — | 1 Participants | — | — | 1 Participants |
| Race (NIH/OMB) Black or African American | — | 0 Participants | — | — | 0 Participants |
| Race (NIH/OMB) More than one race | — | 0 Participants | — | — | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | — | 0 Participants | — | — | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | — | 0 Participants | — | — | 0 Participants |
| Race (NIH/OMB) White | — | 2 Participants | — | — | 2 Participants |
| Region of Enrollment Australia | — | 0 participants | — | — | 0 participants |
| Region of Enrollment Netherlands | — | 0 participants | — | — | 0 participants |
| Region of Enrollment South Korea | — | 0 participants | — | — | 0 participants |
| Region of Enrollment Spain | — | 0 participants | — | — | 0 participants |
| Region of Enrollment United States | — | 3 participants | — | — | 3 participants |
| Sex: Female, Male Female | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Sex: Female, Male Male | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 3 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 3 / 3 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 1 / 3 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Overall Response Rate by RECIST v 1.1
ORR by RECIST v1.1
Time frame: 1 year
Population: All subjects who have at least one measurable lesion at baseline, receive at least 1 infusion of CX-072 DP and have at least 1 postbaseline RECIST 1.1 assessment, or who discontinue treatment/study due to disease progression by RECIST v 1.1.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | Overall Response Rate by RECIST v 1.1 | Complete Response (CR) | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | Overall Response Rate by RECIST v 1.1 | Partial Response (PR) | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | Overall Response Rate by RECIST v 1.1 | Progressive Disease (PD) | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | Overall Response Rate by RECIST v 1.1 | Stable Disease (SD) | 0 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | Overall Response Rate by RECIST v 1.1 | Partial Response (PR) | 0 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | Overall Response Rate by RECIST v 1.1 | Progressive Disease (PD) | 2 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | Overall Response Rate by RECIST v 1.1 | Stable Disease (SD) | 0 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | Overall Response Rate by RECIST v 1.1 | Complete Response (CR) | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | Overall Response Rate by RECIST v 1.1 | Complete Response (CR) | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | Overall Response Rate by RECIST v 1.1 | Progressive Disease (PD) | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | Overall Response Rate by RECIST v 1.1 | Stable Disease (SD) | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | Overall Response Rate by RECIST v 1.1 | Partial Response (PR) | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | Overall Response Rate by RECIST v 1.1 | Progressive Disease (PD) | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | Overall Response Rate by RECIST v 1.1 | Complete Response (CR) | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | Overall Response Rate by RECIST v 1.1 | Partial Response (PR) | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | Overall Response Rate by RECIST v 1.1 | Stable Disease (SD) | 0 Participants |
Secondary
The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST
ORR by irRECIST
Time frame: 2 years
Population: All subjects who have at least one measurable lesion at baseline, receive at least 1 infusion of CX-072 DP and have at least 1 postbaseline irRECIST assessment, or who discontinue treatment/study due to disease progression by irRECIST.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Stable Disease (irSD) | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Complete Response (irCR) | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Progressive Disease (irPD) | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Partial Response (irPR) | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | no target disease identified at baseline and at follow-up (irNN) | 0 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Stable Disease (irSD) | 0 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Partial Response (irPR) | 0 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Progressive Disease (irPD) | 2 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Complete Response (irCR) | 0 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | no target disease identified at baseline and at follow-up (irNN) | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | no target disease identified at baseline and at follow-up (irNN) | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Complete Response (irCR) | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Partial Response (irPR) | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Stable Disease (irSD) | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Progressive Disease (irPD) | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | no target disease identified at baseline and at follow-up (irNN) | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Progressive Disease (irPD) | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Partial Response (irPR) | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Complete Response (irCR) | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST | immune-related Stable Disease (irSD) | 0 Participants |
Secondary
The Percentage of Patients Experiencing Treatment Related Adverse Events
Safety and Tolerability of CX-072 in Combination Therapy
Time frame: 2 years
Population: All subjects who receive any amount of CX-072.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Skin and subcutaneous tissuedisorders - Rash Generalized (treatment related) | Did not experience | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Injury, poisoning and proceduralcomplications - Infusion Related Reaction | Did not experience | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Metabolism and nutrition disorders - Dehydration (treatment related) | Did not experience | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Diarrhea (treatment related) | Experienced | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Skin and subcutaneous tissuedisorders - Rash Generalized (treatment related) | Experienced | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Hepatobiliary Disorders - Immune-mediated Hepatitis (treatment related) | Experienced | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Hepatobiliary Disorders - Immune-mediated Hepatitis (treatment related) | Did not experience | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Diarrhea (treatment related) | Did not experience | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Injury, poisoning and proceduralcomplications - Infusion Related Reaction | Experienced | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Vomitting (treatment related) | Experienced | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Vomitting (treatment related) | Did not experience | 0 Participants |
| Cohort A1: CX-072 in Combination With Anti-cancer Therapy-front Line | The Percentage of Patients Experiencing Treatment Related Adverse Events | Metabolism and nutrition disorders - Dehydration (treatment related) | Experienced | 0 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Diarrhea (treatment related) | Did not experience | 2 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Metabolism and nutrition disorders - Dehydration (treatment related) | Experienced | 1 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Hepatobiliary Disorders - Immune-mediated Hepatitis (treatment related) | Did not experience | 1 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Skin and subcutaneous tissuedisorders - Rash Generalized (treatment related) | Experienced | 1 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Skin and subcutaneous tissuedisorders - Rash Generalized (treatment related) | Did not experience | 2 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Metabolism and nutrition disorders - Dehydration (treatment related) | Did not experience | 2 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Diarrhea (treatment related) | Experienced | 1 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Vomitting (treatment related) | Did not experience | 2 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Vomitting (treatment related) | Experienced | 1 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Hepatobiliary Disorders - Immune-mediated Hepatitis (treatment related) | Experienced | 2 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Injury, poisoning and proceduralcomplications - Infusion Related Reaction | Did not experience | 2 Participants |
| Cohort A2: CX-072 in Combination With Ipilimumab | The Percentage of Patients Experiencing Treatment Related Adverse Events | Injury, poisoning and proceduralcomplications - Infusion Related Reaction | Experienced | 1 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Metabolism and nutrition disorders - Dehydration (treatment related) | Did not experience | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Diarrhea (treatment related) | Experienced | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Diarrhea (treatment related) | Did not experience | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Hepatobiliary Disorders - Immune-mediated Hepatitis (treatment related) | Experienced | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Hepatobiliary Disorders - Immune-mediated Hepatitis (treatment related) | Did not experience | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Vomitting (treatment related) | Experienced | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Vomitting (treatment related) | Did not experience | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Metabolism and nutrition disorders - Dehydration (treatment related) | Experienced | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Skin and subcutaneous tissuedisorders - Rash Generalized (treatment related) | Experienced | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Skin and subcutaneous tissuedisorders - Rash Generalized (treatment related) | Did not experience | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Injury, poisoning and proceduralcomplications - Infusion Related Reaction | Experienced | 0 Participants |
| Cohort A3: CX-072 in Combination With Anti-cancer Therapy-Progressed | The Percentage of Patients Experiencing Treatment Related Adverse Events | Injury, poisoning and proceduralcomplications - Infusion Related Reaction | Did not experience | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Vomitting (treatment related) | Did not experience | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Vomitting (treatment related) | Experienced | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Diarrhea (treatment related) | Experienced | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Skin and subcutaneous tissuedisorders - Rash Generalized (treatment related) | Did not experience | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Hepatobiliary Disorders - Immune-mediated Hepatitis (treatment related) | Did not experience | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Hepatobiliary Disorders - Immune-mediated Hepatitis (treatment related) | Experienced | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Injury, poisoning and proceduralcomplications - Infusion Related Reaction | Did not experience | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Injury, poisoning and proceduralcomplications - Infusion Related Reaction | Experienced | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Metabolism and nutrition disorders - Dehydration (treatment related) | Did not experience | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Metabolism and nutrition disorders - Dehydration (treatment related) | Experienced | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Gastrointestinal disorders - Diarrhea (treatment related) | Did not experience | 0 Participants |
| Cohort B1: CX-072 in Combination With Anti-cancer Therapy-Neoadjuvant | The Percentage of Patients Experiencing Treatment Related Adverse Events | Skin and subcutaneous tissuedisorders - Rash Generalized (treatment related) | Experienced | 0 Participants |